Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

Steroids in Treatment of Viral Encephalitis

Phase 4

Conditions: Encephalitis, Viral

Interventions: Drug: Dexamethasone
Drug: Methylprednisolone

First Posted Date: 2019-09-25

Last Posted Date: 2020-01-29

Lead Sponsor: Assiut University

Target Recruit Count: 100

Registration Number: NCT04103684

Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.

Phase 3

Conditions: Hemophagocytic Lymphohistiocytosis

Interventions: Drug: Pegylated liposomal doxorubicin
Drug: Etoposide
Drug: Methylprednisolone

First Posted Date: 2019-09-04

Last Posted Date: 2019-09-06

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 160

Registration Number: NCT04077905

Locations: 🇨🇳
Beijing Friendship Hospital, Beijing, China

Treg Modulation With CD28 and IL-6 Receptor Antagonists

Phase 1

Completed

Conditions: Living-Donor Kidney Transplant
Kidney Transplant Recipients

Interventions: Biological: lulizumab pegol
Biological: antithymocyte globulin (rabbit)
Drug: methylprednisolone
Biological: tocilizumab
Drug: Prednisone
Drug: everolimus
Biological: belatacept
Drug: mycophenolate mofetil
Drug: mycophenolic acid

First Posted Date: 2019-08-26

Last Posted Date: 2024-10-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT04066114

Locations: 🇺🇸
Cleveland Clinic Foundation: Transplantation, Cleveland, Ohio, United States
🇺🇸
University of California San Francisco School of Medicine: Transplantation, San Francisco, California, United States
🇺🇸
University of Alabama School of Medicine: Transplantation, Birmingham, Alabama, United States

and more 4 locations

A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant

Phase 2

Completed

Conditions: Allografts
Rejection; Transplant, Kidney
Transplant Rejection
Kidney Transplantation

Interventions: Drug: Belatacept
Drug: VIB4920
Drug: Thymoglobulin
Drug: Methylprednisolone

First Posted Date: 2019-08-06

Last Posted Date: 2023-10-10

Lead Sponsor: Viela Bio (acquired by Horizon Therapeutics)

Target Recruit Count: 25

Registration Number: NCT04046549

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Keck Medical Center of USC, Los Angeles, California, United States
🇺🇸
Duke University School of Medicine, Durham, North Carolina, United States

and more 1 locations

GON-injection for a Sooner and Better Treatment of Cluster Headache

Phase 4

Completed

Conditions: Cluster Headache, Episodic
Greater Occipital Nerve Injection

Interventions: Other: Placebo
Drug: Methylprednisolone

First Posted Date: 2019-07-10

Last Posted Date: 2024-03-13

Lead Sponsor: Leiden University Medical Center

Target Recruit Count: 70

Registration Number: NCT04014634

Locations: 🇳🇱
LUMC, Leiden, Zuid Holland, Netherlands
🇳🇱
Tergooi Ziekenhuis, Blaricum, Netherlands
🇳🇱
Zuyderland Medisch Centrum, Heerlen, Netherlands

and more 3 locations

Transplant Antibody-Mediated Rejection: Guiding Effective Treatments

Phase 3

Active, not recruiting

Conditions: Antibody-mediated Rejection
Kidney Transplant Rejection

Interventions: Drug: Methylprednisolone
Drug: Rituximab
Procedure: Plasma Exchange
Drug: Intravenous Immunoglobulin

First Posted Date: 2019-06-21

Last Posted Date: 2021-04-01

Lead Sponsor: Imperial College London

Target Recruit Count: 3

Registration Number: NCT03994783

Locations: 🇬🇧
Imperial College London, London, United Kingdom

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

Phase 4

Completed

Conditions: Gout

Interventions: Biological: Pegloticase
Drug: methotrexate
Dietary Supplement: folic acid
Drug: placebo
Drug: gout flare prophylaxis regimen
Drug: fexofenadine
Drug: acetaminophen
Drug: methylprednisolone

First Posted Date: 2019-06-21

Last Posted Date: 2024-06-26

Lead Sponsor: Amgen

Target Recruit Count: 152

Registration Number: NCT03994731

Locations: 🇺🇸
Arizona Arthritis and Rheumatology Research, PLLC-East, Mesa, Arizona, United States
🇺🇸
Axis Clinical Trials, Los Angeles, California, United States
🇺🇸
Prohealth Research Center, Doral, Florida, United States

and more 57 locations